ProPhase Labs, Inc. (formerly The Quigley Corporation)
PRPH · OTC · United States
Share price · PRPH
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when PRPH's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 6 Aug 2026+25.0%
- 7 Jul 2026+28.6%
Nothing announced by PRPH that day or the session before.
- 23 Jun 2026+37.5%
Nothing announced by PRPH that day or the session before.
- 22 May 2026+22.2%
Nothing announced by PRPH that day or the session before.
- 16 Apr 2026-26.7%
Nothing announced by PRPH that day or the session before.
- 17 Mar 2026-30.8%
Nothing announced by PRPH that day or the session before.
- 28 Jan 2026-27.3%
- 23 Jan 2026+23.8%
- 22 Jan 2026+50.0%
Nothing announced by PRPH that day or the session before.
- 7 Jan 2026-16.0%
Nothing announced by PRPH that day or the session before.
Share of unusual movement by asset
For each asset, the share of PRPH's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
| Other company news (earnings, financing, releases naming no asset) | — | 23% |
| Sessions with no dated event | — | 77% |
No dated announcements about its assets since 2 Jul 2024.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Preclinical / Unstaged | PIM kinases (PIM1/2/3)Small molecule | Solid Tumors |
Discontinued programmes (1)
Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (15)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $1.0M | — | <$0.1M | $3.0M-$0.1M operating cash flow | report ↗ |
View 14 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | $0.5M | — | <$0.1M | $5.3M-$0.8M operating cash flow | report ↗ |
| 2025-Q3 | $0.9M | <$0.1M | $0.4M | $6.8M-$3.5M operating cash flow | report ↗ |
| 2025-Q2 | $1.3M | $0 | $0.2M+ $0 short-term inv. | $4.5M-$0.3M operating cash flow | report ↗ |
| 2025-Q1 | $1.4M | $0.1M | $0.1M | —-$3.4M operating cash flow | report ↗ |
| 2024-Q3 | $3.1M | $0.1M | $0.5M+ $0 short-term inv. | $6.6M-$4.0M operating cash flow | report ↗ |
| 2024-Q2 | $2.5M | $0.1M | $1.8M+ $0 short-term inv. | $6.2M-$4.8M operating cash flow | report ↗ |
| 2024-Q1 | $3.6M | $0.3M | $1.2M+ $0.1M short-term inv. | $6.3M-$5.1M operating cash flow | report ↗ |
| 2023-Q3 | $8.4M | $0.4M | $0.7M+ $2.6M short-term inv. | $5.1M-$4.7M operating cash flow | report ↗ |
| 2023-Q2 | $13M | $0.6M | $3.8M+ $5.3M short-term inv. | $3.4M-$7.0M operating cash flow | report ↗ |
| 2023-Q1 | $19M | $0.1M | $9.6M+ $6.0M short-term inv. | —$0.5M operating cash flow | report ↗ |
| 2022-Q3 | $24M | $0.1M | $23M+ $3.7M short-term inv. | —$2.6M operating cash flow | report ↗ |
| 2022-Q2 | $29M | <$0.1M | $24M+ $3.5M short-term inv. | —$4.8M operating cash flow | report ↗ |
| 2022-Q1 | $48M | <$0.1M | $26M+ $3.5M short-term inv. | —$20M operating cash flow | report ↗ |
| 2021-Q3 | $9.5M | $0.2M | $8.5M+ $14M short-term inv. | $4.0M-$5.5M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $4.3M | $0.1M | $0.1M+ $0 short-term inv. | $3.7M-$8.3M operating cash flow | report ↗ |
For fiscal year 2025, ProPhase Labs reported revenue of $4.35M, down 35.7% YoY, and R&D spend of $0.11M, down 81.4% YoY. Cash and equivalents were $0.09M, and the company reported a net loss of $14.74M, with a quarterly net burn of $14.74M.
During the year, ProPhase continued development of the BE-Smart esophageal pre-cancer diagnostic test in collaboration with mProbe and the Mayo Clinic, as well as the LB-1/LB-2 oncology program with Dana-Farber and Harvard Medical School; Equivir trial final results were pending. The company also sold its Pharmaloz contract manufacturing business effective January 16, 2025, receiving $2M in cash and extinguishing roughly $11M in debt, and its ProPhase Diagnostics subsidiaries filed for Chapter 11 bankruptcy on September 22, 2025 and were deconsolidated.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $6.8M | $0.6M | $0.7M+ $0 short-term inv. | $13M-$18M operating cash flow | report ↗ |
| 2023-FY | $44M | $1.4M | $1.6M+ $3.1M short-term inv. | $4.2M-$11M operating cash flow | report ↗ |
| 2022-FY | $123M | $0.7M | $9.1M+ $8.3M short-term inv. | —$29M operating cash flow | report ↗ |
| 2021-FY | $79M | $0.5M | $8.4M+ $8.8M short-term inv. | —-$14M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2025-09-09 | Karkus Ted William · director, CEO & CHAIRMAN | Award / grant (derivative) | 500,000 | — | — | Form 4 |
| 2025-02-17 | Hollenshead Stuart · Chief Operating Officer | Award / grant (derivative) | 500,000 | — | — | Form 4 |
| 2025-02-14 | GLECKEL LOUIS MD · director | Award / grant (derivative) | 100,000 | — | — | Form 4 |
| 2025-02-14 | Hirsch Warren · director | Award / grant (derivative) | 100,000 | — | — | Form 4 |
| 2024-03-17 | Karkus Ted William · director, CEO & CHAIRMAN, 10% owner | Award / grant (derivative) | 400,000 | — | — | Form 4 |
| 2024-03-17 | Karkus Ted William · director, CEO & CHAIRMAN, 10% owner | Award / grant (derivative) | 400,000 | — | — | Form 4 |
| 2024-03-17 | Barr Jason Michael · director | Award / grant (derivative) | 70,000 | — | — | Form 4 |
| 2024-03-17 | GLECKEL LOUIS MD · director | Award / grant (derivative) | 70,000 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 2 reporting institutions held 0.0M shares ($2, 0.0% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Farther Finance Advisors, LLC | 10 | $1 |
| 2 | CoreCap Advisors, LLC | 10 | $1 |